NCT01474525

Brief Summary

This Randomized Controlled Trial (RCT) will test the efficacy of a home blood glucose telemonitoring system against usual care in women with gestational diabetes mellitus (GDM) or type 2 diabetes mellitus (T2DM) during pregnancy. We hypothesize that the system can improve glycemic control in patients, assessed using the mean blood glucose during gestation as the primary outcome measure.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 20, 2011

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 18, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

November 21, 2011

Status Verified

November 1, 2011

Enrollment Period

2.2 years

First QC Date

July 20, 2011

Last Update Submit

November 17, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester

    An average of 12 weeks.

    from the baseline to the delivery date

Secondary Outcomes (8)

  • Mean fasting and post-prandial blood glucose by trimester

    from the baseline to the delivery date

  • Percentage of values within recommended guidelines

    from the baseline to the delivery date

  • Adherence: Percentage of values recorded over expected number of values

    from the baseline to the delivery date

  • Adherence: Average number of values per day

    from the baseline to the delivery date

  • Onset of labour and mode of delivery

    at exit (delivery)

  • +3 more secondary outcomes

Study Arms (2)

Telemonitoring

EXPERIMENTAL
Device: Home Blood Glucose Telemonitoring System

Usual Care

ACTIVE COMPARATOR
Device: Home Blood Glucose Telemonitoring System

Interventions

The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface. Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.

TelemonitoringUsual Care

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patients must be pregnant
  • diagnosed with gestational diabetes or Type 2 diabetes
  • must be comfortable with instructions in English and be able to express themselves using simple phrases in English.

You may not qualify if:

  • unable to complete self monitoring of blood glucose (SMBG) for any reason
  • uncomfortable with the use of the telemonitoring equipment
  • develop an acute illness requiring hospitalization, where they may deviate from the normal delivery of care
  • refusal to sign consent form or to carry out the demands made by the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mount Sinai Hospital, Leadership Sinai Centre for Diabetes

Toronto, Ontario, M5T 3L9, Canada

RECRUITING

Related Publications (6)

  • HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.

    PMID: 18463375BACKGROUND
  • Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. doi: 10.1056/NEJMoa042973. Epub 2005 Jun 12.

    PMID: 15951574BACKGROUND
  • Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet. 2002 May 11;359(9318):1690-2. doi: 10.1016/S0140-6736(02)08599-9. No abstract available.

    PMID: 12020549BACKGROUND
  • Langer O. Type 2 diabetes in pregnancy: exposing deceptive appearances. J Matern Fetal Neonatal Med. 2008 Mar;21(3):181-9. doi: 10.1080/14767050801929497.

    PMID: 18297573BACKGROUND
  • Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29 Suppl D:S153-60. doi: 10.1016/j.clinthera.2007.12.015.

    PMID: 18191067BACKGROUND
  • Yang J, Cummings EA, O'connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol. 2006 Sep;108(3 Pt 1):644-50. doi: 10.1097/01.AOG.0000231688.08263.47.

    PMID: 16946226BACKGROUND

MeSH Terms

Conditions

Diabetes, GestationalDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Alexander G Logan, MD, FRCP(C)

    MOUNT SINAI HOSPITAL

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexander G Logan, MD, FRCP(C)

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 20, 2011

First Posted

November 18, 2011

Study Start

January 1, 2010

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

November 21, 2011

Record last verified: 2011-11

Locations